Shiseido Beauty Innovations Fund announces investment in Trautec as lead investor

The Shiseido Beauty Innovations Fund, established by Shiseido Company, Limited’s (“Shiseido”) China subsidiary, Shiseido China Co., Ltd., and Boyu Capital announces its first investment in Jiangsu Trautec Medical Technology Co., Ltd. (Trautec). Shiseido will act as the lead investor with an investment of close to RMB 100 million. Furthermore, Shiseido will form a strategic partnership with Trautec to work together in areas such as product R＆D, raw material supply, and sales channels to accelerate the exploration of new areas in functional skincare *1.

Established in 2015, Trautec is dedicated to the development and production of recombinant collagen*2-based biomaterials for mainly medical and cosmetics industries. As the pioneer of the industry, Trautec operates the full value chain from R＆D, manufacturing, to distribution, by holding multiple intellectual property rights in the development of recombinant collagen, and owning its production plant located in Changzhou, Jiangsu Province. The market of functional skincare, which offers specific functions to skin, is growing significantly as more and more Chinese consumers are looking for effective solutions to their skin problems. The needs for recombinant collagen are expanding because of its stability and effectiveness as well as wide application to medical, healthcare and cosmetics fields.

Shiseido Beauty Innovations Fund explores investment opportunities among China’s emerging companies in cosmetics and wellness, as well as in related technology companies such as e-commerce and digital services. Through the fund, Shiseido will fuse the values of itself and emerging companies to enhance its business portfolio in China to meet the diversifying consumer needs and to steadily strengthen the China business, which is one of the pillars of the company’s Medium-to-Long-Term Strategy “WIN 2023 and Beyond”.

*1 Functional skincare is the skincare that offers specific functions to skin, such as sensitive skin, aging care or clean beauty
*2 Recombinant collagen produced by biosynthesis is non animal produced collagen

＜About Trautec＞
Company Name: Jiangsu Trautec Medical Technology Co., Ltd.
Year of Establish: 2015
Location: Jiangsu Province, China
Main Business: R＆D, production, and sales of new biomaterials and innovative protein/ nucleic acid drugs
Website: http://www.trautec.com.cn/index.php?lang=en